CD74, a key receptor for macrophage migration inhibitory factor (MIF), has been implicated in cancer prognosis; CD74+ neutrophils are associated with improved patient outcomes in multiple malignancies by inducing antigen-specific T-cell responses and fostering an immunogenic (“hot”) tumor microenvironment, suggesting their potential as an immunotherapy-sensitizing strategy (78, 79). The gene discussed is MIF; the disease is cancer.